Volume 6, Issue 2 (Summer-Fall 2023)
Mod Med Lab J 2023, 6(2): 8-12 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rahmanifar F, Mussin N, Tamadon A. Advances in mesenchymal stromal/stem cell therapy for non-obstructive azoospermia: a comprehensive mini-review. Mod Med Lab J 2023; 6 (2) :8-12
URL: http://modernmedlab.com/article-1-142-en.html
URL: http://modernmedlab.com/article-1-142-en.html
Abstract: (432 Views)
Azoospermia, characterized by the absence of sperm in semen, poses a significant challenge to male fertility. Mesenchymal stromal/stem cell (MSC) therapy has emerged as a promising approach for treating azoospermia by promoting spermatogenesis and restoring fertility. MSCs possess the ability to differentiate into male germ cells and create a favorable microenvironment for spermatogenesis through the secretion of growth factors and cytokines. Preclinical studies have shown encouraging results, with improved testicular histology, sperm production, and fertility outcomes in animal models of azoospermia. Limited clinical studies in humans have also demonstrated the potential of MSC therapy in restoring spermatogenesis. However, challenges such as standardization of MSC isolation, characterization, and administration protocols, as well as the need for long-term safety and efficacy data, remain to be addressed. Despite these challenges, MSC therapy holds great promise for the treatment of azoospermia and warrants further research to optimize its use in clinical practice.
Keywords: Azoospermia, Mesenchymal Stem Cell Transplantation, Spermatogenesis, Male Infertility, Testicular Diseases
Type of Study: Review Article |
Subject:
Stem Cell and Regenerative Medicine
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
